«Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV - related vulvar
and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females,
and approximately 90 percent of HPV - related anal cancer
and genital
warts in males
and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.